EARLY MORNING TRAVELERS SHOULD DRIVE WITH CARE – Plunging temperatures overnight create conditions for black ice on roadways

EARLY MORNING TRAVELERS SHOULD DRIVE WITH CARE
Plunging temperatures overnight create conditions for black ice on roadways

CULPEPER — Roads in the Virginia Department of Transportation’s Culpeper District are mostly clear of snow but drivers should still be alert for black ice, particularly on secondary roads, bridges and overpasses.

Overnight temperatures dropped well into the teens and any moisture left on roadways has refrozen into black ice. Bridges and overpasses, lightly-traveled secondary roads, intersections and crossovers are the most likely locations where drivers will encounter slick conditions. VDOT crews worked overnight responding to reports of slippery conditions.

Drivers who plan to travel over the New Year’s holiday should check road conditions using VDOT’s free 511 tools and use caution on bridges, ramps, overpasses and other areas prone to freezing.

Additional information about winter-weather preparations and response can be found at www.virginiadot.org/travel/snow.asp. Local updates are posted to Twitter.com/VaDOTCulp and on the district’s snow information webpage.

VDOT’s Culpeper District includes the counties of Albemarle, Culpeper, Fauquier, Fluvanna, Greene, Louisa, Madison, Orange and Rappahannock.

(END)

Information in VDOT news releases was accurate at the time the release was published. For the most current information about projects or programs, please visit the project or program Web pages. You may find those by searching by keyword in the search Virginia DOT box above.

Page last modified: Dec. 31, 2017

Activity Level and Barriers to Participate of Cardiac Rehabilitation in Advanced Heart Failure Patients

Brief Summary:

A prospective longitudinal and observational clinical study will be conducted with hospitalized heart failure patients.The main purpose is to know the level of physical activity of these patients after their discharge in relation to the orientation received during their hospitalization and identify the barriers perceived by these patients to participate in a cardiac rehabilitation program. The outcomes are available by telephone calls in 30 and 90 days after discharge.

Condition or disease
Heart Failure,Congestive Cardiac Rehabilitation Physical Exercise

Detailed Description:

Heart failure is a progression epidemic problem, parallel to population aging. The costs of this disease are estimates in 38 billion of dollars per year, many of those have a relationship to high number of hospitalizations and decompensated heart failure. Non-adherence to drug treatment and non-pharmacological measures as cardiac rehabilitation are the major causes of high number of mortality and hospitalizations by heart failure. Our objectives will be to identify in decompensated heart failure inpatients the level of physical activity that they done before hospitalization, the barriers for the non-use of cardiac rehabilitation and their disposition to changes of lifestyle. Correlation between level of physical activity and readmission in 30 and 90 days after hospital discharge will be done. To understand the profile of these patients and difficulties for to do physical exercise could help to make future actions with focus in to obtain high adherence to changes in lifestyle.

Examining Carryover Effect in Patients Treated witH Spinal cOrd Stimulation (ECHO)

Spinal cord stimulation is a minimally invasive surgical treatment for severe, chronic, neuropathic pain that is refractory to conventional treatment.

The treatment consists of an electrode implanted in the epidural space of the spinal cord, either via a percutaneous approach (using the so-called percutaneous leads) or via a surgical (hemi-) laminectomy (using the so-called surgical leads or plate leads).

It is a well-known clinical observation that when activating or deactivating SCS stimulation, there is a variable interval before the patient perceives a clinical effect of the change. This variation goes by different names (carryover, echo, after effect, etc.) and might be dependent on the clinical condition and treatment duration. To our knowledge only very little research has been published on the topic of carryover effects; a recent study showed that the interval is highly variable between patients.

While patients may experience immediate pain relief at the onset of SCS treatment, the effect in patients with a long-term SCS treatment history may have different characteristics, possibly due to ongoing changes in the nervous system.

The aim of this pilot study is to lay the foundation for investigating the carryover effects in spinal cord stimulation.

This will be carried out in a mixed population of patients with different indications for SCS, and with different treatment durations.

Patients will be asked to deactivate their device via their remote control or with a magnet in a standardized fashion.

They will be asked to reactivate the device when specific parameters have been met, and the time is recorded.

In the post-hoc analysis the carryover and reverse carryover effect will be analyzed and correlated to a number of parameters including, but not limited to: Indication, treatment duration, symptom duration, preoperative pain score, stimulation paradigm, gender, age.

Data will be collected and stored using a dedicated REDCap database under the auspices of Aarhus University.

Biomarkers and Validation of Selected Outcome Measures (CMTNSmod)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03386266
Recruitment Status : Active, not recruiting

First Posted : December 29, 2017

Last Update Posted : December 29, 2017

Sponsor:

Collaborators:

Information provided by (Responsible Party):

Brief Summary:

CMT is a rare disease for which novel treatments are being developed. Evaluation of intervention efficacy is hampered by slow progression and lack of sensitive outcome measures. Primary goal of the project is to identify and validate RNA and protein derived biomarkers in blood of CMT patients for selected outcome measures over 2 years. The investigators expect to develop more responsive outcome measures and circulating biomarkers to improve assessment of intervention efficacy in forthcoming therapeutic trials.

Charcot-Marie-Tooth Disease, Type IA

Detailed Description:

Novel treatments are being developed for CMT. Intervention efficacy evaluation is hampered by slow disease progression and lack of sensitive outcome measures. The investigators have previously shown that biomarkers from skin identified in a CMT1A rat model can be translated to CMT1A patients. Primary goal is to identify circulating biomarkers correlating with disease severity and progression. 210 young, adolescent and adult patients affected by genetically confirmed CMT1A, will be evaluated with different clinical outcome measures, assessing impairment, disability and quality of life: Patients will be re-evaluated at 12 (n=147) and 24 months (n=103) with the same measures to assess disease progression. A number of candidate markers correlating with disease severity have been identified in blood samples from the rat model of CMT1A. At 0-12-24 months a blood sample will be drawn from affected CMT1A patients. The investigators will purify total mRNA from blood samples, and validate the 10 strongest regulated markers identified in the rat model via qRTPCR in blood of CMT1A patients. Protein biomarkers will also be analysed. Marker expression at baseline and at follow up will be correlated with clinical severity and progression. In this translational project (rat/human) the investogators expect to develop more responsive outcome measures and circulating biomarkers to improve assessment of intervention efficacy in forthcoming therapeutic trials.

Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Biomarkers and Validation of Selected Outcome Measures (CMTNSmod)
Actual Study Start Date : August 11, 2017
Estimated Primary Completion Date : January 31, 2019
Estimated Study Completion Date : September 30, 2019

Primary Outcome Measures :

  1. mRNA Expression Levels in blood samples from CMT1A patients [ Time Frame: 3 years ]

    Validation of key candidate genes (GSST2, FN3KRP, CTSA, SPRR1A) fro former studies

  2. mRNA Expression Levels in Skin biopsies from CMT1A patients [ Time Frame: 3 years ]

    Validation of key candidate genes (GSST2, FN3KRP, CTSA, SPRR1A) fro former studies

Biospecimen Retention:   Samples With DNA

DNA and RNA from blood and skin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   3 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample

Patients suffering from CMT1A disease

Inclusion Criteria:

  • Clinical diagnosis of CMT1A
  • Genetic confirmation of PMP22 duplication (for adults patients)
  • Children aged 3-11, adolescents aged 12-17 and adults aged 18-65 years
  • Signed informed patient consent

Exclusion Criteria:

  • Other causes of neurological and psychiatric disorders
  • Severe internistic disease
  • Patient known or suspected to be alcohol / drug abuser
  • Pregnancy, breast feeding period
  • Permanent Vitamin C intake
  • Participation an interventional clinical study up to 4 weeks prior to inclusion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03386266

University Medical Center Goettingen
Goettigen, Lower Saxony, Germany, 37075

University Medical Center Goettingen

University Hospital Muenster

Ludwig-Maximilians – University of Munich

Principal Investigator: Michael W. Sereda, MD, Professor of Neurology University Medical Center Goettingen
Publications:

Responsible Party: Michael W Sereda, MD, Professor of Neurology, University Medical Center Goettingen
ClinicalTrials.gov Identifier: NCT03386266     History of Changes
Other Study ID Numbers: 05171
First Posted: December 29, 2017    Key Record Dates
Last Update Posted: December 29, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Michael W Sereda, MD, Professor of Neurology, University Medical Center Goettingen:

Biomarkers
CMT1A
Charcot-Marie-Tooth disease

Additional relevant MeSH terms:

Tooth Diseases
Charcot-Marie-Tooth Disease
Nerve Compression Syndromes
Hereditary Sensory and Motor Neuropathy
Stomatognathic Diseases
Nervous System Malformations
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Polyneuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Congenital Abnormalities
Genetic Diseases, Inborn

Graduation Ceremony for 49 New Nashville Police Officers is Tomorrow Night

December 18, 2017

FOR IMMEDIATE RELEASE       

The Nashville Police Department will welcome 49 new police officers tomorrow (Tuesday) night as the recruit class known as Session 82 formally completes 5½ months of rigorous physical and classroom training.       

The graduation ceremony is scheduled for 6 p.m. at First Baptist Church Joelton, 7140 Whites Creek Pike.  Mayor Barry and Chief Anderson will preside and deliver congratulatory remarks.       

The public is invited.                                                         

###

Accused Murderer Racardo Spencer Returned to Nashville

December 18, 2017

FOR IMMEDIATE RELEASE     

Accused murderer and convicted felon Racardo Spencer is back in Nashville after MNPD officers returned him today from Kentucky.  Spencer, 31, who is under indictment for the June 22nd fatal shooting of Timothy Orlando White in the 600 block of 41st Avenue North, was arrested September 8th in Oak Grove, Kentucky, near the Tennessee border.       

Spencer received two eight-year sentences, which were mostly probated, in February of this year in regard to aggravated assault with a deadly weapon and felony drug convictions.  He received a four-year sentence in 2008 for reckless homicide.      

Spencer is being held without bond pending proceedings in Criminal Court.                                                        

###

Racardo A. Spencer, 31 

Public reminded to pay attention to marine safety when participating in major events at sea

Public reminded to pay attention to marine safety when participating in major events at sea

******************************************************************************************

Attention radio/TV announcers:
      
Please broadcast the following at suitable intervals:

     With regard to the New Year’s Eve countdown celebrations to be held tonight (December 31), the Marine Department reminds members of the public to pay attention to marine safety when viewing the display at sea. Parents or adults should look after children and ensure that children are wearing a lifejacket at all times. Coxswains should keep a passenger and crew list in case it is needed. In addition, passengers should note the locations of emergency exits and lifejackets, as well as how to put on a lifejacket, before the vessel departs. Coxswains should refrain from speeding or overloading their vessels.
      
     Marine Department Notice No. 180 of 2017 has been issued regarding special marine traffic control and safety measures for tonight. Members of the public can visit the department’s website for more details (www.mardep.gov.hk).

 

Ends/Sunday, December 31, 2017
Issued at HKT 13:00

NNNN

Car park at Hong Kong Wetland Park full

Car park at Hong Kong Wetland Park full

***************************************

Attention TV/radio announcers:
 
Please broadcast the following as soon as possible:
 
     The car park at Hong Kong Wetland Park is full. Motorists going to the Park can use the nearby public car parks at Tin Heng Estate, Tin Yat Estate, Grandeur Terrace or Tin Yip Road.
 
     Members of the public are encouraged to take public transport to the Park.

 

Ends/Sunday, December 31, 2017
Issued at HKT 12:29

NNNN

VDR Gene Polymorphisms and Weight Loss in Non-diabetic Overweight and Obese Subjects

This is a six months intervention study in non-diabetic overweight and obese subjects. Subjects will be counseled for weight loss through diet and exercise. Diet and exercise will be recommended as per the regular norms for weight loss (weight loss ≥10% from baseline weight will be considered as a significant loss of weight) for overweight and obese subjects. A sample size of 90 subjects was calculated but assuming a drop out rate of 20%, 110 subjects will be enrolled. Enrolled subjects will be measured at every visit (monthly) for weight, body composition measures of abdominal obesity and skin folds. They would be assessed for compliance with diet and exercise. Detailed analysis of body composition including DXA, biochemical analysis will be performed at enrollment and after six months intervention. Statistical analysis will be performed to find association between measures of body composition for weight loss and genotypes of the VDR polymorphisms.

This is a six months intervention study in non-diabetic overweight and obese subjects. Subjects will be counseled for weight loss through diet and exercise. Diet and exercise will be recommended as per the regular norms for weight loss (weight loss ≥10% from baseline weight will be considered as a significant loss of weight) for overweight and obese subjects. A sample size of 90 subjects was calculated but assuming a drop out rate of 20%, 110 subjects will be enrolled. Enrolled subjects will be measured at every visit (monthly) for weight, body composition measures of abdominal obesity and skin folds. They would be assessed for compliance with diet and exercise. Detailed analysis of body composition including DXA, biochemical analysis will be performed at enrollment and after six months intervention. Statistical analysis will be performed to find association between measures of body composition for weight loss and genotypes of the VDR polymorphisms.

VDR Polymorphisms

Polymorphisms in the VDR gene have been identified through out the complete VDR gene region and associated with cancer and autoimmune diseases. The FokI polymorphism is present in the translation site and results in the VDR protein being shortened by three amino acids and is not linked with any other VDR polymorphisms. This polymorphism predisposes to bone-disease, risk of cancer, immune mediated diseases 147-149,150, 151.

The common VDR gene polymorphisms are BsmI, TaqI, ApaI and FokI. These polymorphisms have shown varying results with insulin sensitivity and secretion.

Antibacterial-coated Sutures at Time of Cesarean

Experimental: Plus group (Triclosan-coated Sutures)

Use of Monocryl Plus, Vicryl Plus and PDS Plus Suture (Triclosan-coated sutures) will be used exclusively throughout the entire procedure.

Device: Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)

The intervention consists of using Antibacterial-coated sutures during cesarean delivery.

Other Name: Plus group